FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 8,090,000 shares, a growth of 8.4% from the May 31st total of 7,460,000 shares. Based on an average trading volume of 2,320,000 shares, the days-to-cover ratio is currently 3.5 days.

Analyst Upgrades and Downgrades

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research report on Monday, June 3rd.

Insider Buying and Selling

In other FibroGen news, insider Deyaa Adib purchased 22,123 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was bought at an average price of $1.17 per share, with a total value of $25,883.91. Following the completion of the purchase, the insider now directly owns 82,123 shares of the company’s stock, valued at approximately $96,083.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On FibroGen

Several large investors have recently modified their holdings of FGEN. Armistice Capital LLC raised its position in shares of FibroGen by 23.7% in the 4th quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after purchasing an additional 1,872,000 shares during the last quarter. Pennant Investors LP purchased a new position in shares of FibroGen in the 4th quarter worth about $681,000. Public Employees Retirement System of Ohio increased its holdings in FibroGen by 1,472.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 165,364 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in FibroGen in the 4th quarter worth about $136,000. Finally, Algert Global LLC increased its holdings in FibroGen by 488.4% in the 3rd quarter. Algert Global LLC now owns 161,550 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 134,094 shares in the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Trading Down 7.0 %

Shares of FibroGen stock opened at $0.69 on Thursday. The firm has a market capitalization of $68.73 million, a P/E ratio of -0.28 and a beta of 0.71. The business has a fifty day simple moving average of $1.13 and a two-hundred day simple moving average of $1.41. FibroGen has a 12 month low of $0.33 and a 12 month high of $3.02.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.02). The firm had revenue of $55.90 million during the quarter, compared to analysts’ expectations of $41.00 million. Analysts predict that FibroGen will post -1.05 earnings per share for the current year.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.